146 related articles for article (PubMed ID: 35318162)
21. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
22. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
Sugimoto T; Shiraki M; Fukunaga M; Kishimoto H; Hagino H; Sone T; Nakano T; Ito M; Yoshikawa H; Minamida T; Tsuruya Y; Nakamura T
Osteoporos Int; 2019 Nov; 30(11):2321-2331. PubMed ID: 31392401
[TBL] [Abstract][Full Text] [Related]
23. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
[TBL] [Abstract][Full Text] [Related]
24. Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report.
Catalano A; Vita GL; Russo M; Vita G; Lasco A; Morabito N; Messina S
Osteoporos Int; 2016 Dec; 27(12):3655-3659. PubMed ID: 27589974
[TBL] [Abstract][Full Text] [Related]
25. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
26. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
Bilezikian JP
Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the efficacy of teriparatide treatment for osteoporosis on lumbar fusion surgery outcomes: a systematic review and meta-analysis.
Fatima N; Massaad E; Hadzipasic M; Shankar GM; Shin JH
Neurosurg Rev; 2021 Jun; 44(3):1357-1370. PubMed ID: 32728969
[TBL] [Abstract][Full Text] [Related]
28. Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report.
Javinani A; Aghaei Meybodi HR; Kavosi H
J Med Case Rep; 2020 Jul; 14(1):87. PubMed ID: 32616027
[TBL] [Abstract][Full Text] [Related]
29. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
30. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
[TBL] [Abstract][Full Text] [Related]
31. Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study.
Thorsteinsson AL; Vestergaard P; Eiken P
Arch Osteoporos; 2015; 10():35. PubMed ID: 26427867
[TBL] [Abstract][Full Text] [Related]
32. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
Bonafede MM; Shi N; Bower AG; Barron RL; Grauer A; Chandler DB
Osteoporos Int; 2015 Mar; 26(3):1203-12. PubMed ID: 25567774
[TBL] [Abstract][Full Text] [Related]
33. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
Dobnig H
Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
[TBL] [Abstract][Full Text] [Related]
34. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
35. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH
Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Osteoporosis With Anabolic Agents and the Risk of Primary Bone Cancers: A Study of 44,728 Patients Treated With Teriparatide and Abaloparatide.
McDonald CL; Johnson K; Alsoof D; Molino J; Balmaceno-Criss M; Daniels AH
J Am Acad Orthop Surg; 2023 May; 31(10):520-528. PubMed ID: 36913523
[TBL] [Abstract][Full Text] [Related]
37. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
38. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
[TBL] [Abstract][Full Text] [Related]
39. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
Sugimoto T; Shiraki M; Fukunaga M; Hagino H; Sone T; Nakano T; Kishimoto H; Ito M; Yoshikawa H; Kishida M; Irie C; Nakamura T
Adv Ther; 2017 Jul; 34(7):1727-1740. PubMed ID: 28631217
[TBL] [Abstract][Full Text] [Related]
40. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
